Text Size

Increasing Screening for Type 2 Diabetes in Women With Previous Gestational Diabetes.

This study has been completed.
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by:
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT00212914
First received: September 13, 2005
Last updated: September 8, 2008
Last verified: September 2008
History of Changes
  Purpose

In 1998, The Canadian Diabetes Association published guidelines that recommended women diagnosed with gestational diabetes mellitus (GDM,) should be screened postpartum for Type 2 diabetes using a glucose tolerance test. We determined the rate of screening for Type 2 diabetes at the Ottawa Hospital before and after the publication of this guideline and found that none of the women in either period had been screened following this recommendation. We believe a reminder letter outlining the recommended screening test sent to the patient and/or her family physician would increase screening for Type 2 diabetes in women with previous GDM.


Condition Intervention
Gestational Diabetes
 Behavioral: Reminder letter

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Official Title: Mailing Recommendations to the Individual or Physician to Increase Screening for Type 2 Diabetes in Women With Previous Gestational Diabetes: Clinical Trial.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Ottawa Hospital Research Institute:

Primary Outcome Measures:
  • The proportion of patients screened in each group

Estimated Enrollment: 268
Study Start Date: May 2002
Estimated Study Completion Date: January 2006
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All women, who are pregnant and attend the High Risk Pregnancy Unit and who have been diagnosed with Gestational Diabetes will be considered for inclusion in the study.

Exclusion Criteria:

  • 1. Patient does not have a Family Physician 2. Patient's Family Physician already has a patient enrolled in the study 3. Patient already enrolled in the study for a previous pregnancy 4. Unable to give informed consent in English or French 5. History of pre-gestational diabetes mellitus 6. Intra-uterine fetal death or still birth
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00212914

Locations
Canada, Ontario
The Ottawa Hospital, Civic Campus, High Risk Unit
Ottawa, Ontario, Canada, K1Y 1J7
Sponsors and Collaborators
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator: Heather Clark, MD OHRI
  More Information

No publications provided by Ottawa Hospital Research Institute

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00212914     History of Changes
Other Study ID Numbers: CIHR- KTE 110023
Study First Received: September 13, 2005
Last Updated: September 8, 2008
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes, Gestational
Glucose Metabolism Disorders
 Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications

ClinicalTrials.gov processed this record on May 21, 2013